

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO. 8503	
09/992,660	11/14/2001	Paul D. Johnson	00118.USI		
25533 7	590 02/28/2003				
PHARMACIA & UPJOHN			EXAMINER		
301 HENRIETTA ST 0228-32-LAW			SAEED, KAMAL A		
KALAMAZOO, MI 49007			ART UNIT	PAPER NUMBER	
			1626		
			DATE MAILED: 02/28/2003	DATE MAILED: 02/28/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N	lo.	Applicant(s)				
	09/992,660		JOHNSON ET AL.				
Office Action Summary	Examiner		Art Unit				
Office Action Carring,	Kamal A Sae	nd.	1626				
The MAU ING DATE of this communication an							
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
1)⊠ Responsive to communication(s) filed on <u>15</u>	April 2002 .						
,— .	his action is no	n-final.					
3) Since this application is in condition for allow	wance except fo	r formal matters, pr	osecution as to the merits is				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-42</u> is/are pending in the application.							
4a) Of the above claim(s) <u>28-36</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)☐ Claim(s) is/are rejected.	6) Claim(s) is/are rejected.						
7) Claim(s) <u>1-27,34 and 37-42</u> is/are objected to							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority docume	nts have been r	eceived.					
	2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)	•						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5		y (PTO-413) Paper No(s). <u>5</u> . Patent Application (PTO-152)				

	Application No.		Applicant(s)			
	09/992,660		JOHNSON ET AL.			
Interview Summary	Examiner		Art Unit			
	Kamal A Saeed	l 	1626			
All participants (applicant, applicant's representative, PTO personnel):						
(1) <u>Kamal A Saeed</u> . (3)						
(2) <u>Lucy X. Yang</u> .	(4)					
Date of Interview: 19 February 2003.						
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant	2) applicant	s representativ	e]			
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e) No.					
Claim(s) discussed: <u>1-42</u> .						
Identification of prior art discussed:						
Agreement with respect to the claims f) was reached	d. g)⊡ was no	t reached. h)[□ N/A.			
Substance of Interview including description of the gene reached, or any other comments: <u>an election was made to compounds of Formula I, and the species of Example</u> (A fuller description, if necessary, and a copy of the ame allowable, if available, must be attached. Also, where no allowable is available, a summary thereof must be attached.	e with traverse to e 41, page 60, endments which the o copy of the ame hed.)	Group I, claims ne examiner agendments that v	greed would render the claims would render the claims			
i) It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).						
Unless the paragraph above has been checked, THE FOMUST INCLUDE THE SUBSTANCE OF THE INTERVIENCE ACTION HAS Already been filed, APPLICANT IS GIVEN OF STATEMENT OF THE SUBSTANCE OF THE INTERVIEWERS FOR THE INTERVIEWERS F	EW. (See MPEP NE MONTH FRO	Section 713.04 M THIS INTER	I). If a reply to the last Office			
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.	1	Examiner's sig	nature, if required			



Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by
 attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does
 not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check the appropriate box at the bottom of the Form which informs the applicant that the submission of a separate record of the substance of the interview as a supplement to the Form is not required.

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
 - (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Art Unit: 1626

DETAILED ACTION

Claims 1-42 are pending in this application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-27, 34, and 37-42, are drawn to compounds and compositions of formula I, as defined in claim 1, variously classified in classes 540, 549, 514 and several subclasses.

II. Claims 28-36, are drawn to a method of use of compounds variously classified, in classes 544, 549 and several subclasses.

The inventions are distinct, each from the other because of the following reasons:

Invention Groups I and II are related as product and method of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different method of using the product (MPEP 806.05(h)). In the instant case, the product as claimed can be used in a materially different method of using the product as demonstrated throughout the specification and in claims 28-36 which are directed to several methods of using the product, for example treating eye infection, skin infection etc. Therefore a separate search considerations are involved, which would impose a burden if unrestricted.

Accordingly, along with the election of one of the above groups, the following action is also taken.

Art Unit: 1626

Claim 1 is generic to a plurality of disclosed patentably distinct species comprising, for example, the compounds of (1) Example 41, page 60; Example 50, page 66; (2) a method of treating eye infection, skin infection, etc using the compounds as in Example 41, etc. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purpose as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

In accordance with M.P.E.P. 821.04 and In re Ochiai, 71 F.3d 1565, 37 USPQ 1127 (Fed. Cir. 1995), rejoinder of product claims with process claims commensurate in scope with the allowed product claims will occur following a finding that the product claims are allowable.

Until such time, a restriction between product claims and process is deemed proper.

Additionally, in order to retain the right to rejoinder in accordance with the above policy,

Applicant is advised the process of use are amended during prosecution to maintain either

Art Unit: 1626

dependency on the product claims or to otherwise include limitations of the product claims.

Failure to do so may result in a loss of the right to rejoinder.

Response to Restriction

During a telephone conversation with Applicants' representative, Lucy X. Yang, on 02/19/2003, an election was made with traverse to Group I, claims 1-27, 34 and 37-42 directed to

compounds of Formula I, and the species Example 41, page 60,

 $N-\{3-[3-(2-Hydroxy-acetyl)-2,3,4,5-tetrahydro-1H-benzo[d]\ azepin-7-yl]-oxazolidin-5-ylmethyl\}-a$ $cetamide \qquad . \ Claims$

The traversal is on the ground(s) that each of the elected Group could be extended to other groups without imposing an undue burden on the Examiner. This is not found persuasive because each of the various Groups is directed to art recognized compounds which are different from each other and, are capable of supporting their own patents. Moreover, the examiner is required to conduct a commercial data base search on the class and each subclass. This would be an undue burden on the examiner.

Therefore, the restriction requirement deemed proper and is made FINAL.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicants preserve their right to file a divisional on the non-elected subject matter.

Art Unit: 1626

Status of the Claims

Claims 1-42 are pending in this application. The generic concept of the elected subject matter is as follows:

Compound of formula I, of claim 1, wherein

 $X \text{ is } NR^3$; G is N; $E \text{ is } CH_2$; Q is CH; O is O; W is O or S;

 \mathbf{R}^1 is H, C_{1-8} alkyl, C_{3-6} cycloalkyl, OC_{1-4} alkyl, SC_{1-4} alkyl, NH_2 , NHC_{1-6} alkyl or $N(C_{1-6}$ alkyl)₂; \mathbf{R}^2 is H, halo or C_{1-4} alkyl;

 $\mathbf{R}^3 - \mathbf{R}^9$ are as defined with the exception that they don't represent a heterocyclic group; \mathbf{m} is 2; and \mathbf{n} is 2.

As a result of the election and the corresponding generic concept identified, the remaining subject matter of claims 1-27, 34 and 37-42 and Group II, claims 28-36 are withdrawn from further consideration pursuant to 37 CFR 1.142 (b) as being drawn to non-elected inventions. The withdrawn subject matter of claims 1-27, 34 and 37-42 is properly restricted as it differs materially in structure and in element from the elected subject matter supra so as to be patentably distinct there from, i.e., a reference which anticipated but the elected subject matter would not even render obvious the withdrawn subject matter and the fields of search are not coextensive.

Objections

Claims 1-27, 34 and 37-42 are objected to for containing non-elected subject matter.

Claims drawn solely to the elected invention as identified supra, would appear allowable. Group II, claims 28-36, drawn to methods of use of compounds of formula I, would be allowable along with the elected invention and commensurate in scope therewith.

Art Unit: 1626

The claims must be amended to exclude non-elected subject matter and within the limit of elected compounds of formula I.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal Saeed whose telephone number is (703) 308-4592. The examiner can normally be reached on Monday-Friday from 8:00 AM – 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (703) 308 4537. The unofficial fax phone for this group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signiture, may be used by applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.



Art Unit: 1626

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-2286.

Kamal Saeed, PhD February 20, 2003

Joseph K. M. Kano Joseph K. McKane,

Supervisory Patent Examiner Art Unit 1626, Group 1626

Technology Center 1